Global Action Plan for Influenza Vaccines (GAP) is a comprehensive strategy to reduce the present global shortage of influenza vaccines for seasonal epidemics and pandemic influenza in all countries of the world through three major approaches:
The plan was developed by WHO together with public health, academic experts, vaccine manufactures and funding agencies from developed and developing countries during a consultation held in 2006 in Geneva.
Since the publication of the GAP (GAP I) in 2006, great strides have been made towards better preparedness for an influenza pandemic: new and expanded facilities have been announced in both developed and developing countries; the amount of antigen required per dose is now lower thanks to new adjuvants; production yields have improved; and progress is being made with new technologies.
From GAP I to GAP II
Lessons learned from the 2009 (H1N1) pandemic and ongoing sporadic outbreaks of H5N1 have highlighted the issues addressing the access, affordability and effective deployment of pandemic vaccines by countries that have limited or no such access.
WHO together with the partners will address these issues in the new Global Action Plan for Influenza Vaccines - GAP II that will provide succession for the activities of GAP I. GAP II will refine the objectives of GAP I and will provide a roadmap for technical implementation and sustainable approach to pandemic preparedness and future funding needs.
GAP is participated by three WHO technical clusters:
World Health Organization
Global Action Plan for Influenza Vaccines (GAP)
20, avenue Appia
1211 Geneva 27, Switzerland
Key WHO Information
Director-General and senior management
Governance of WHO
WHO Constitution, Executive Board and World Health Assembly
News, events, fact sheets, multimedia and contacts
International travel and health
Publication on travel risks, precautions and vaccination requirements
World Health Report
Annual report on global public health and key statistics